Sarcoidosis, PulmonaryPhase 4CAESARNCT05841758
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
A Phase 4 study testing Hydroxychloroquine in people with Sarcoidosis, Pulmonary, run by Hospices Civils de Lyon at 21 sites in France.
Trial summary
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sarcoidosis, Pulmonary
- What is being tested?
- Hydroxychloroquine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 140 participants
- Where
- 21 sitesFrance
- Study dates
- 30 Jul 2024to 1 Jul 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- at least 18 years of age
- pathologically proven sarcoidosis as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) criteria
- non severe ocular sarcoidosis requiring systemic treatment
- non severe skin sarcoidosis requiring systemic treatment
- non severe osseous sarcoidosis requiring systemic treatment
- non severe sarcoidosis with joint involvement requiring systemic treatment
Show all 14Show fewer
- non severe sarcoidosis-related hypercalcemia requiring systemic treatment
- non severe peripheral nervous system sarcoidosis requiring systemic treatment
- non severe sarcoidosis-related non-severe Ear, Nose and Throat (ENT) involvement requiring systemic treatment
- symptomatic hypercalciuria >200 mg/24h (24 h urine) OR
- - > 20 mg/mmol creatinine on urine sample
- - > 180 mg/g creatinine on urine sample
- signed informed consent
- affiliated to National French social security system
Who cannot join
- severe sarcoidosis involvement requiring another immunosuppressant or anti-TNF antibody or methylprednisolone i.v. pulses
- previous (<3 months before screening) or concurrent treatment with immunosuppressants
- previous treatment with corticoid (patient weaned for 3 months before inclusion)
- previous treatment with antimalarial drugs (HCQ/CQ) (patient must have been off plaquenil for at least 12 months)
- treatment with citalopram, escitalopram, hydroxyzin, domperidone and piperaquine
- known hypersensitivity or intolerance to HCQ/CQ or 4-aminoquinoline derivatives and prednisone
Show all 20Show fewer
- heart rhythm disorders on EKG (QT prolongation) (except atrial fibrillations)
- severe ophthalmological impairment or ophthalmological impairment that does not allow ophthalmic monitoring; previous history of maculopathy or retinopathy
- end-stage lung, liver, cardiac, or renal disease
- sarcoidosis with central nervous system involvement
- cardiac sarcoidosis
- clinical evidence of active infection (including infection with herpes virus and varicella-zoster virus) or severe/unstabilized comorbidity (e.g. moderate to severe heart failure) or unstabilized psychosis
- chronic viral (HIV or HBV) infection
- untreated latent/active tuberculosis
- pregnancy or lactation (βHCG will be test by blood analysis at inclusion)
- concurrent vaccination with live vaccines during therapy
- inability to understand information about the protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study
- patient participating in other interventional research
- persons under court protection
- Use of effective contraception for the duration of the study . (Contraception is considered effective when it consists of one of the following: use of a male condom during all sexual activity and/or efficient oral hormonal contraception (better considered combined contraception) and/or an intrauterine device (IUD) and/or hormone-releasing intrauterine system (IUS) and/or history of bilateral tubal ligation and/or history of vasectomy, provided the male partner is the trial participant's only sexual partner and/or sexual abstinence)
Trial locations and contacts
21 sites in 1 country. Contact the study team or a site near you to ask about taking part.
21 sites in 1 country
France21 sites, 21 recruiting
- Recruiting
Service de Médecine Interne Infectiologie Aïgue Polyvalente- Hôpital Henri Duffaud
Avignon, 84 000
Philip Bielfed, Dr, 04 32 75 30 01, BIELEFELD.Philip@ch-avignon.fr
Philip Bielfed, Dr
- Not yet recruiting
Service de Pneumologie - Hôpital Avicenne
Bobigny, 93000
Hilario Nunes, Dr, 01 48 95 51 25 ext. 33, hilario.nunes@aphp.fr
Hilario Nunes, Dr
- Not yet recruiting
Service de medecine interne - Hôpital Henri Mondor
Créteil, 94000
Matthieu Mahévas, Dr, 01 49 81 20 76 ext. 33, matthieu.mahevas@aphp.fr
Matthieu Mahévas, Dr
- Not yet recruiting
Service de Médecine Interne et Immunologie Clinique - CHU Dijon Bourgogne
Dijon, 21 079
Bernard Bonnotte, Dr, 03 80 29 34 32, bernard.bonnotte@chu-dijon.fr
Bernard Bonnotte, Dr
- Not yet recruiting
Service de medecine interne - Hôpital Claude Huriez
Lille, 59 000
Emmanuel LEDOULT, Dr, 03 20 44 50 48, emmanuel.ledoult2@chu-lille.fr
Emmanuel LEDOULT
- Not yet recruiting
Service de medecine interne - Hôpital Duputryen
Limoges, 87 042
Kim Ly, Dr, 05 55 05 69 90, kim.ly@chu-limoges.fr
Kim Ly, Dr
- Recruiting
Service de médecine interne - Hôpital de la Croix Rousse
Lyon, 69004
Thomas El JAMMAL, Dr, 04.26.73.26.36, thomas.el-jammal@chu-lyon.fr
Thomas EL JAMMAL, MD
- Not yet recruiting
Service de médecine interne - Hôpital Edouard Herriot
Lyon, 69004
Barba Thomas, Dr, 04 72 11 77 91 ext. 33, Thomas.barba@chu-lyon.fr
Thomas Barba, Dr
- Recruiting
Service de médecine interne - Hôpital Lyon Sud
Lyon, 69004
Reynaud Quitterie, Dr, 04 78 86 13 54, Reynaud.quitterie@chu-lyon.fr
Reynaud Quitterie, Pr
- Not yet recruiting
Service de médecine interne - Centre Hospitalier Saint Joseph Saint Luc
Lyon, 69007
Laurent Perard, Dr, 04 78 61 83 08 ext. 33, lperard@ch-stjoseph-stluc-lyon.fr
Laurent Perard, Dr
- Not yet recruiting
Service de medecine interne - Hôpital Saint Eloi
Montpellier, 34 295
Sophie Rivière, Dr, 04 67 33 05 94, s-riviere@chu-montpellier.fr
Sophie Rivière, Dr
- Not yet recruiting
Service de medecine interne - Hôpital Hôtel Dieu
Nantes, 44000
Antoine Néel, Dr, 02 40 08 33 55, mohamed.hamidou@chu-nantes.fr
Antoine Néel, Dr
- Not yet recruiting
Service de médecine interne - Hôpital Lariboisière
Paris, 75010
Damien Sène, Dr, 01 49 95 63 21, damien.sene@aphp.fr
Damien Sène, Dr
- Not yet recruiting
Service de medecine interne 2- Hôpital de la Pitié-Salpétrière
Paris, 75013
Fleur Cohen, Dr, 01 42 17 81 66, Fleur.cohen@aphp.fr
Fleur Cohen, Dr
- Not yet recruiting
Hôpital Cochin - Médecine interne
Paris
Alexis REGENT, MD, 158411455 ext. +33, alexis.regent@aphp.fr
Alexis REGENT, MD
- Not yet recruiting
Hôpitaux Saint Joseph et Marie LANNELONGUE
Paris
Jean-Marc NACCACHE, MD, 144127582 ext. +33, jmnaccache@ghpsj.fr
Jean-Marc NACCACHE, MD
- Recruiting
Service de Médecine Interne et maladies infectieuses - Hôpital Haut Lévêque
Pessac, 33 604
Jean-François Viallard, 05 57 65 64 83, jean-francois.viallard@chu-bordeaux.fr
Jean-François Viallard, MD
- Recruiting
Service de Médecine Interne et Immunologie Clinique - Hôpital Sud
Rennes, 35 2000
Nicolas Belhomme, Dr, 02 99 26 71 28, nicolas.belhomme@chu-rennes.fr
Nicolas Belhomme, dr
- Not yet recruiting
Service de medecine interne - Hôpital Nord
Saint-Etienne, 42 055
Killian Martin, Dr, 04 77 82 83 42, pascal.cathebras@chu-st-etienne.fr
Killian Martin, Dr
- Recruiting
Service de médecine interne - Clinique Saint exupéry
Toulouse, 31077
Martin Michaud, Dr, 05 61 17 33 33 ext. 33, Martin.MICHAUD@clinique-saint-exupery.com
Martin Michaud, Dr
- Not yet recruiting
CHU Tours - Médecine interne
Tours
Stéphanie JOBARD, MD, 218370882 ext. +33, s.jobard@chu-tours.fr
Stéphanie JOBARD, MD
About this study
Official title: Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized Trial
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis.
When indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series/reports have shown CQ/HCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ/HCQ are daily used for skin, bone, and joint sarcoidosis, as well as hypercalcemia. Nowadays, HCQ is preferred over CQ because of a lower incidence of gastrointestinal and ocular adverse reactions, which can be minimized by close attention to the dosage and regular retinal examination. Its profile of safety is well-known since it has long been employed to treat systemic lupus erythematous or rheumatoid arthritis. Its action is thought to rely on its ability to accumulate in lysosomes of phagocytic cells, to affect antigen presentation and reduce pro-inflammatory cytokines. The investigator hypothesize that HCQ may be an efficacious add-on therapy for extra-pulmonary sarcoidosis leading to a significant steroid-sparing effect.
- Conditions
- Sarcoidosis, Pulmonary
- Being tested
- Hydroxychloroquine, Placebo
- Keywords
- Sarcoidosis, Hydroxychloroquine, steroid-sparing agent, Extra pulmonary sarcoidosis
- Medical subject headings
- Sarcoidosis, Pulmonary, Sarcoidosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
PlaceboDrug
Placebo during a 12 months double blind placebo-controlled period
| Study group | Role | What they receive |
|---|---|---|
| Hydroxychloroquine | Experimental | prednisone (scheduled protocol) + hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period, then according to the treating the physician for an additional open period of 12 months) Receives: Drug: Hydroxychloroquine |
| Placebo arm | Placebo comparator | prednisone (scheduled protocol) + placebo (1-2 tablets/day during a 12 months double blind placebocontrolled period, then the treatment is left to the physician's discretion until M24) Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the steroid-sparing effect of hydroxychloroquine as an add-on therapy in patients with non severe extra-pulmonary sarcoidosis requiring a systemic treatment.
The primary endpoint is the percentage of patients in remission and off prednisone at month 9, without relapse until month 12. The primary endpoint will thus be assessed at M12.
Remission is defined by either complete or partial response. Complete response is defined as the absence of clinical or paraclinical sign of disease activity. Partial response is defined as the persistence of clinical or paraclinical sign of disease activity, which do not require substantial treatment modification (high dose CS, immunosuppressant or anti-Tumor Necrosis Factor (TNF) drugs). Relapse is defined as the persistence, or recurrence of existing manifestations and/or the occurrence of new sarcoidosis manifestations requiring substantial treatment modification.
Measured: at Year 1
Secondary outcomes (14)
Organ-specific response assessed by the extra-pulmonary Physician Organ Severity Tool (ePOST)
score comprised between 0 and 6
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
rate of complete, partial, stable or progression of the disease
Global clinical response will be assessed by the physician as complete, partial, stable, or progression
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess the total dose of local steroid treatments
Total dose in Gramme of local steroid treatments
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess the efficacy of HCQ in maintaining the relapse-free survival over a prolonged period
Relapse rate
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess and compare the eventual reduction of steroid-related toxicity (side effects)
Frequencies of steroid-associated side-effects monitored clinically and biologically
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess HCQ safety
HCQ safety will be assessed through initial and annual electroretinogram
Measured: at Month 3, Month 6 and Month 12
Assess HCQ safety
HCQ safety will be assessed through initial and annual autofluorescence
Measured: at Month 3, Month 6 and Month 12
Assess HCQ safety
HCQ safety will be assessed through initial and annual electroretinogram or autofluorescence or Optical Coherence Tomography (OCT), yearly eye evaluation and monitoring of eventual Adverse Event (AE)s. An AE will be considered as serious if it leads to HCQ cessation, hospitalization, or death.
Measured: at Month 3, Month 6 and Month 12
Assess HCQ safety
HCQ safety will be assessed through yearly eye evaluation with monitoring of eventual Adverse Event (AE)s. An AE will be considered as serious if it leads to HCQ cessation, hospitalization, or death.
Measured: at Month 3, Month 6 and Month 12
Assess HCQ safety
HCQ safety will be assessed through Optical Coherence Tomography (OCT)
Measured: at Month 3, Month 6 and Month 12
Assess patients' adherence
Patient's adherence will be controlled by patient notebooks
Measured: at Month 3, Month 6 and Month 12
Assess patients' adherence
Patient's adherence will be controlled by pharmacy count of returned tablets
Measured: at Month 3, Month 6 and Month 12
Assess patients' adherence
Patient's adherence will be controlled by serial dosages of blood HCQ levels
Measured: at Month 3, Month 6 and Month 12
Assess quality of life by the Study Short Form 36 questionnaire (SF-36 questionnaire).
11 questions are asked, the minimum score is 36 and the maximum score is 149. Statistical analysis of the SF-36 questionnaire will be performed by a statician, analysis is more complex than only higher score means better health.
Measured: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2023
- Study start30 Jul 2024
- Primary completion1 Jul 2029 (estimated)
- Study completion1 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcoidosis, PulmonaryStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05841758
- Sponsor's protocol ID
- 69HCL21_1054
- Other IDs
- 2022-502155-65-00
- Acronym
- CAESAR
- Status last verified
- Sep 2026
- First submitted
- 17 Mar 2023
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized Trial
- ClinicalTrials.gov ID
- NCT05841758
- Acronym / sponsor ID
- CAESAR / 69HCL21_1054
- Conditions
- Sarcoidosis, Pulmonary
- Keywords
- Sarcoidosis, Hydroxychloroquine, steroid-sparing agent, Extra pulmonary sarcoidosis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 30 Jul 2024 (actual)
- Primary completion
- 1 Jul 2029 (estimated)
- Study completion
- 1 Jul 2029 (estimated)
- First posted
- 3 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis.
When indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series/reports have shown CQ/HCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ/HCQ are daily used for skin, bone, and joint sarcoidosis, as well as hypercalcemia. Nowadays, HCQ is preferred over CQ because of a lower incidence of gastrointestinal and ocular adverse reactions, which can be minimized by close attention to the dosage and regular retinal examination. Its profile of safety is well-known since it has long been employed to treat systemic lupus erythematous or rheumatoid arthritis. Its action is thought to rely on its ability to accumulate in lysosomes of phagocytic cells, to affect antigen presentation and reduce pro-inflammatory cytokines. The investigator hypothesize that HCQ may be an efficacious add-on therapy for extra-pulmonary sarcoidosis leading to a significant steroid-sparing effect.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hydroxychloroquine | Experimental | Drug: Hydroxychloroquineprednisone (scheduled protocol) + hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period, then according to the treating the physician for an additional open period of 12 months) |
| Placebo arm | Placebo comparator | Drug: Placeboprednisone (scheduled protocol) + placebo (1-2 tablets/day during a 12 months double blind placebocontrolled period, then the treatment is left to the physician's discretion until M24) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
Key exclusion criteria (20 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HydroxychloroquineHydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period) | Drug | Hydroxychloroquine |
| PlaceboPlacebo during a 12 months double blind placebo-controlled period | Drug | Placebo arm |
Primary outcome
Evaluate the steroid-sparing effect of hydroxychloroquine as an add-on therapy in patients with non severe extra-pulmonary sarcoidosis requiring a systemic treatment.
Time frame: at Year 1
The primary endpoint is the percentage of patients in remission and off prednisone at month 9, without relapse until month 12. The primary endpoint will thus be assessed at M12. Remission is defined by either complete or partial response. Complete response is defined as the absence of clinical or paraclinical sign of disease activity. Partial response is defined as the persistence of clinical or paraclinical sign of disease activity, which do not require substantial treatment modification (high dose CS, immunosuppressant or anti-Tumor Necrosis Factor (TNF) drugs). Relapse is defined as the persistence, or recurrence of existing manifestations and/or the occurrence of new sarcoidosis manifestations requiring substantial treatment modification.
14 secondary outcomes
Organ-specific response assessed by the extra-pulmonary Physician Organ Severity Tool (ePOST)
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
rate of complete, partial, stable or progression of the disease
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess the total dose of local steroid treatments
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess the efficacy of HCQ in maintaining the relapse-free survival over a prolonged period
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess and compare the eventual reduction of steroid-related toxicity (side effects)
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Assess HCQ safety
Time frame: at Month 3, Month 6 and Month 12
Assess HCQ safety
Time frame: at Month 3, Month 6 and Month 12
Assess HCQ safety
Time frame: at Month 3, Month 6 and Month 12
Assess HCQ safety
Time frame: at Month 3, Month 6 and Month 12
Assess HCQ safety
Time frame: at Month 3, Month 6 and Month 12
Assess patients' adherence
Time frame: at Month 3, Month 6 and Month 12
Assess patients' adherence
Time frame: at Month 3, Month 6 and Month 12
Assess patients' adherence
Time frame: at Month 3, Month 6 and Month 12
Assess quality of life by the Study Short Form 36 questionnaire (SF-36 questionnaire).
Time frame: at Month 0, Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
Related trials for Sarcoidosis, Pulmonary
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
Not yet recruitingPhase 2
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Pulmonary Sarcoidosis
Not yet recruitingPhase 2
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
Sarcoidosis Associated Pulmonary Hypertension
Not yet recruitingPhase 2/3
Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Not yet recruitingPhase 2
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Pulmonary Sarcoidosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
21 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Hydroxychloroquine in people with Sarcoidosis, Pulmonary, run by Hospices Civils de Lyon at 21 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 21 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thomas El Jammal, Dr (04.26.73.26.29 ext. 33, thomas.el-jammal@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the steroid-sparing effect of hydroxychloroquine as an add-on therapy in patients with non severe extra-pulmonary sarcoidosis requiring a systemic treatment. (time frame: at Year 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.